Viatris Inc (VTRS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $23.87B
Last updated: Nov 17, 2026 at 11:05 AM ET
Viatris Inc (VTRS) P/E Ratio & Valuation History
Viatris (VTRS) trades at 8.1x trailing earnings and 1.6x sales. Its P/E of 8.1x is above its 5-year median of 3.7x. Its forward P/E is 7.6x. The median P/E across 10 similar companies is 19.9x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 6.6% higher over the next year. Its free cash flow yield is 8.9%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 8.1x |
| Forward P/E | 7.6x |
| Price to sales | 1.6x |
| Price to book | 1.7x |
| EV/EBITDA | 12.8x |
| Price to FCF | 11.3x |
| EV/FCF | 16.7x |
| PEG | 3.8 |
| FCF yield | 8.9% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 8.1x | 3.7x | N/A |
| P/S | 1.6x | 0.9x | N/A |
| P/B | 1.7x | 0.7x | N/A |
Valuation History
Over the 6 year ends shown, its P/E ranged from 3.3x in 2022 to 5.3x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $12.45 | 5.3x | 1.0x | 1.0x |
| 2024 | $12.45 | 4.7x | 1.0x | 0.8x |
| 2023 | $10.83 | 3.7x | 0.8x | 0.6x |
| 2022 | $11.13 | 3.3x | 0.8x | 0.6x |
| 2021 | $13.53 | 3.7x | 0.9x | 0.8x |
| 2020 | $18.74 | 4.3x | 0.9x | 0.7x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VTRS
What is VTRS's forward P/E ratio?
Viatris has a forward P/E ratio of 7.6x.
Is VTRS stock overvalued?
GNG's valuation label for VTRS is Overvalued. Its P/E of 8.1x compares with a median of 19.9x across 10 similar companies.
What is VTRS's price to sales ratio?
Viatris has a price to sales ratio of 1.6x.
What is Viatris's average P/E ratio over 5 years?
Viatris's median P/E over the last 5 years is 3.7x, from 60 month-end values through Oct 2026.
What is VTRS's PEG ratio?
Viatris has a PEG ratio of 3.8.
VTRS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts